KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA.
This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused tracks on bioassay development, immunogenicity prediction and assessment, clinical impact, and immunology for biotherapeutics, the program offers a comprehensive platform for scientific collaboration, regulatory discussion, and innovation.
See Us at Our Booth:
Visit us at Booth #6 where our distinguished team members, Lindsay Rutherford, Ph.D., and Tom Sposito, will share KCAS Bio’s own experience with immunogenicity and bioassay science development.
See the full event program here.
Advancing Immunogenicity and Bioassay Science at KCAS Bio
KCAS Bio is a leader in immunogenicity and bioassay science, specializing in the development of regulatory-aligned strategies and assays that drive the safe and effective advancement of biotherapeutics. From predictive immunogenicity risk assessment to anti-drug antibody (ADA) assay development and interpretation, our integrated approach helps clients understand the functional and clinical relevance of their therapies. Our expertise spans a wide range of modalities, and our advanced platforms allow us to adapt our methodologies to reflect the unique biology of each modality. With a deep understanding of immune response and therapeutic function, we deliver data that supports every stage of development.
Our team is dedicated to helping clients navigate the evolving scientific and regulatory landscape with clarity and confidence, while remaining adaptable as industry needs and standards continue to change.
Engaging with Experts to Drive Success
Engaging in the Immunogenicity & Bioassay Summit reflects KCAS Bio’s ongoing mission to connect, advance, and shape the scientific disciplines that drive the future of biologic drug development. We are proud to be exhibiting to share our expertise and hear from you about how we can drive more success in the industry.
At KCAS Bio, we are continuously evolving our technologies and approaches to meet the growing demands of complex biologics, gene therapies, and novel modalities. Through active participation and open scientific exchange, we’re committed to enabling smarter, faster therapeutic development.
Let’s Talk About Your Project Goals
Connect with our team at the Immunogenicity and Bioassay Summit to discuss the ins and outs of biologic drug development. Whether you’re refining a bioassay strategy, addressing immunogenicity in novel modalities, or preparing for regulatory review, KCAS Tom and Lindsay are ready to discuss how KCAS Bio can support your goals with tailored scientific solutions.